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Cutaneous Melanoma in Childhood and Adolescence
Shows Frequent Loss of INK4A and Gain of KIT
Maria Daniotti1,7, Andrea Ferrari2,7, Simona Frigerio3, Paola Casieri4, Francesca Miselli4, Elisa Zucca1,
Paola Collini4, Gabriella Della Torre3, Siranoush Manoukian5, Bernard Peissel5, Aldo Bono6,
Mario Santinami6, Giorgio Parmiani1, Licia Rivoltini1, Silvana Pilotti4,7 and Monica Rodolfo1,7
Childhood cutaneous melanoma is a rare disease with increasing incidence. It is not clear whether it differs
from adult melanoma in etiology and clinical evolution. To genetically characterize childhood melanoma, 21
pediatric patients were studied by germ-line analysis of CDKN2A, CDK4, and MC1R genes. In addition,
alterations in CDKN2A, c-Kit, BRAF, and NRAS genes were evaluated at the somatic level by direct gene
sequencing, fluorescence in situ hybridization analysis, and immunohistochemistry. As a control group of
susceptible patients, we studied patients from 23 melanoma-prone families. At the germ-line level, CDKN2A and
MC1R gene variants were detected in 2/21 and 12/21 pediatric patients and in 9/23 and 19/22 in familial patients.
At the somatic level, most lesions (9/14) from pediatric patients showed CDKN2A locus homozygous deletions
and a null p16 immunophenotype, whereas most lesions (5/8) from familial patients were disomic and
immunoreactive. A c-Kit low-polysomy profile seems to parallel CDKN2A homozygous deletions in pediatric
melanoma whereas the single activating mutation observed segregates with familial patients. Loss of KIT protein
expression was frequent (7/14) in pediatric melanomas, where metastatic cases were prevalent. BRAFV600E
mutation occurred at a similar rate (B50%) in lesions from pediatric and familial patients, whereas no NRAS
mutations were detected.
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INTRODUCTION
Cutaneous melanoma (CM) is an uncommon disease of
children, representing 1–3% of all pediatric malignancies.
CM is rare, as it occurs at a frequency of about 2% under the
age of 20 years (Pappo, 2003) and 0.3–0.4% before puberty
(Huynh et al., 2005). However, an increase in this rate has
been observed in Europe (Schmid-Wendtner et al., 2002) and
in the United States (Strouse et al., 2005; Linabery and Ross,
2008) over the past 10–20 years. The risk of melanoma is
higher in children with giant congenital melanocytic nevi,
dysplastic nevus syndrome, atypical and numerous acquired
melanocytic nevi, xeroderma pigmentosum, immunodefi-
ciency states, or a family history of melanoma (Schaffer,
2007). Besides these predisposing factors, it is not clear
whether childhood melanoma differs from adult melanoma in
etiology, natural history, or prognosis, although prognostic
information suggests a favorable course especially in pre-
pubescent children and in adolescents (Ferrari et al., 2005;
Bleyer et al., 2008). A recent review of the cases treated at our
institute noted the peculiarity of the clinical presentation and
evolution, with a higher frequency of atypical clinical features,
particularly in childhood (Ferrari et al., 2005; Lange and Balch,
2005). These issues have been confirmed in some reports
(Lange et al., 2007) but not in others (Livestro et al., 2007).
In light of the insights gained recently regarding the
demographics and clinical onset/outcome of pediatric
melanoma, a genetic characterization of pediatric melano-
mas is still lacking, and the role of a predisposing genetic
component is still elusive. With few exceptions, the
occurrence of germ-line CDKN2A mutations outside a
familial context is exceedingly rare in childhood (Whiteman
et al., 1997; Youl et al., 2002; Berg et al., 2004). Moreover,
molecular changes involved at the somatic level are also
poorly investigated in pediatric melanoma lesions. However,
this piece of information is important for a molecular
classification of the pediatric melanoma lesions and the
development of rationally designed therapies.
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To genetically profile childhood melanoma, we performed
germ-line and somatic analysis of a cohort of pediatric cases,
including children and teenagers, treated at our institute
for which samples were available. For a control cohort
with genetic susceptibility, we studied adult melanoma
patients from melanoma kindreds. Results are discussed in
comparison to the CM genetic profiles obtained in previous
studies.
RESULTS
Patients
Among 21 ‘‘pediatric’’ patients, including children and
teenagers, there were 12 males and 9 females, ages 2–19
(mean age at diagnosis 12 years). Primary melanomas were
localized to the head in nine patients, in the trunk in nine
patients, and in the extremities in two patients, whereas for
one patient the primary tumor was unknown. Most primary
tumor lesions were 41mm thick, and patients were at
different American Joint Committee on Cancer stages at
diagnosis (IA–IV). The clinical and histopathology data
associated with the primary tumor are detailed in Table S1.
The clinical data related to some of these cases were
previously reported (Bartoli et al., 1994; Terenziani et al.,
2003; Bono and Ferrari, 2005; Ferrari et al., 2005). Tumoral
samples were available for genetic analysis for 11 patients
(Table 1). Lesions from 10 ‘‘familial’’ patients were also
studied in comparison (Table 1). This series included five
women and five men, aged 27–60. Most primary tumor
lesions were o1mm thick. Patients were selected for the
study on the basis of the availability of tumor tissue, only
one index case per family was considered, and both carriers
and noncarriers of CDKN2A germ-line mutations were
Table 1. Disease characteristics and tumor samples analyzed from the pediatric (P) and familial (F) patients
included in this study1
Sample
Patient Sex Age
Primary tumor
body site AJCC stage
Status at
follow-up
(month) Primary2 Metastasis
Peripheral
blood Nevus
1P F 14 Face IIA NED (121) 3.52, IV, NU — — —
2P M 14 Trunk IA NED (37) 0.52, II, NU — — —
3P M 16 Face IB NED (7) 7.2, V, U — PB —
4P F 11 Head IIA NED (55) P1, P2, P33 — PB —
5P M 11 Trunk IIIA NED (12) P1, P24 LN PB —
6P F 2 Ear IIIC NED (26) 1.5, V, NU LN PB —
7P F 17 Trunk IIIC MR (13)1 — LN, OVM — —
8P M 14 Trunk IIIC MR (42)1 — SCM1, SCM2 PB —
9P F 6 Forearm III NED (140) — LN — —
10P M 14 Face IIA DOD (22) — LN1, LN2 — —
11P M 19 Trunk IV DOD (5) UCM — PB —
1F F 43 Trunk IA NED (166) 0.78, III, NU — PB —
2F M 30 Leg IB NED (49) 0.82, IV, NU — PB N1, N2, N35
3F F 50 Neck IA NED (110) 0.69, III, NU — PB —
4F F 27 Trunk I NED (176) — — PB nj
5F F 40 Shoulder III NED (108) — LN PB —
6F M 59 Leg IB NED (91) 0.18, II, U — — —
7F M 47 Arm NA DOD6 — — PB ndj
8F M 49 Head IIA NED (14) 1.66, IV, U — PB —
9F F 50 Arm IIIB NED (36) — CM PB —
10F M 60 Ear IA NED (15) 0.85, II, NU — PB —
AJCC, American Joint Committee on Cancer staging system; CM, cutaneous metastasis; DOD, died of disease; F, female; LN, lymph node metastasis; M,
male; MR, metastatic relapse; ndj, dysplastic junctional nevus; NED, no evidence of disease; nj, junctional nevus; NU, nonulcerated; OVM, ovarian
metastasis; PB, peripheral blood; SCM, subcutaneous metastasis; U, ulcerated; UCM, unclassified melanoma.
1Patient 7P lost during follow-up, patient 8P in progression at 46 months.
2Primary tumors are defined by Breslow thickness, Clark level, and ulceration according to the AJCC staging system.
3Three primary tumor samples of patient 4P are evaluated: P1 (2.25, IV, NU), P2 (1.12, IV, NU), P3 (1.6, IV, NU).
4Two primary tumor samples of patient 5P are evaluated: P1 (5, IV, U), P2 (0.55, IV, NU).
5N1, N2, and N3 nevi from patient 2F were respectively nj (junctional nevus), nc (compound nevus), and cdc (congenital dysplastic compound).
6Follow-up not available.
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included (Table S2). In addition, for germ-line analysis 13
other index cases from different melanoma kindreds were
analyzed.
Somatic alterations in CDKN2A, KIT, BRAF, and NRAS genes in
pediatric melanoma
CDKN2A gene. We examined deletions at the 9p chromo-
somal region in the tumoral tissues by fluorescence in situ
hybridization (FISH) analysis. Two different probes were
used for hybridization to the CDKN2A locus, and both
returned similar results. Most pediatric melanoma lesions
showed CDKN2A gene loss (9/14 lesions from 6/8 patients),
and this result is confirmed by the analysis of p16 protein
level by immunohistochemistry (IHC; Table 2). Although
the numbers of analyzed samples are little and the available
lesions are not matched for stage of progression, the
occurrence of alterations is higher than that observed
in familial melanoma patients, where it is shown in
3/8 cases.
More specifically, in the pediatric cases FISH analysis
showed homozygous deletions (HDs) in three cases (1P, 8P,
and 9P) and monosomy in one case (7P). In two cases
(10P and 6P) two different samples were available from
each patient. The first displayed HD and hemizygous
deletion in two different samples from the same synchronous
metastatic regional lymph nodes (Figure 1(f–j) and (k–o)).
The second case showed a monosomic pattern in the
primary tumor with HD in the regional nodal metastasis.
Only two cases showed a wild-type hybridization pattern.
Consistently, samples that showed HD and monosomy
(all but one, 6P sample) tested negative for p16 protein
expression by IHC staining, whereas disomic samples
Table 2. Summary of the IHC, FISH, and molecular data of p16 and c-Kit genes
p16/ARF FISH
Patient Sample p16 IHC1 I2 probe Gene/CEP9 c5 probe Gene/CEP9 KIT IHC1 KIT FISH2
KIT seq2 exons
9-11-13-17-18
1P P  HD B0 HD B0  Low polysomy wt3
3P P + Disomy B1 Disomy B1 + Disomy wt
5P P1 + Disomy B1 Disomy B1  Disomy wt3
LN + Disomy B1 Disomy B1  Disomy (N495N)
P2 + Disomy B1 Disomy B1  Disomy wt
6P P + Monosomy B1 Monosomy B1 + wt3
LN  HD B0 HD B0 + Disomy (Y494Y)
7P LN  Monosomy B1 Monosomy B1 + Disomy (L862L)4
OVM  Monosomy B1 Monosomy B1  Disomy (L862L)4
8P SCM1  HD B0 HD B0 + Low polysomy wt
SCM2  HD B0 HD B0 + Low polysomy
9P LN  HD B0 HD B0  Low polysomy IVS17+18G4A
10P LN1  HD B0 HD B0 + Low polysomy
LN2  HeD B0.5  Monosomy
1F P  HeD B0.5 HeD B0.5 + Disomy wt
2F P + Disomy B1 Disomy B1 + Disomy S864F
3F P + Disomy B1 Disomy B1 wt3
5F LN  Trisomy B0.7  Low polisomy wt3
6F P + Disomy B1 Disomy B1 + Disomy wt
8F P + Disomy B1 Disomy B1  Disomy wt
9F CM  HeD B0.5 HeD B0.5 + Disomy wt3
10F P + Monosomy B1 Monosomy B1 + Disomy (L862L)
CM, cutaneous metastasis; FISH, fluorescence in situ hybridization; HD, homozygous deletion; HeD, hemizygous deletion; IHC, immunohistochemistry;
LN, nodal metastasis; OVM, ovarian metastasis; P, primary melanoma; SCM, subcutaneous metastasis; wt, wild type.
Blanks in the chart represent samples that were unable to be evaluated; mutations are shown in bold; synonymous polymorphisms or silent alterations are
indicated in brackets.
1IHC analysis is represented with a  in the absence of protein showed by negative staining, and with a + indicating presence of protein shown by positive
staining.
2seq, sequence analysis.
3KIT exons analyzed are the following, patients 1P, 5P sample P1, 9F: exons 11-13-17; patient 6P: exons 9-11-17-18; patient 3F: exons 13-17; patient 5F:
exons 9-13-17-18.
4Homozygosity.
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showed both cytoplasmic and nuclear staining (Figure 1). The
case of patient 6P showed monosomy and positive p16
protein expression in the primary tumor, with a null p16
immunophenotype and CDKN2A HD in the metastatic
regional lymph node. Altogether these data indicate that
alterations at CDKN2A are important in pediatric melanoma
development, mainly through sustaining a multiclonal tumor
progression pattern.
c-Kit gene. The c-Kit gene was analyzed in tumoral
samples by sequencing, FISH, and IHC. The majority of
pediatric melanoma lesions (10/14) show c-Kit alterations,
including sequence alterations, gains or losses of the gene,
and loss of the encoded protein (Table 2). However,
the gene alterations detected were silent or intronic (patients
5P, 6P, and 9P), whereas the c-Kit gene status corresponded
to a ‘‘low-polysomy’’ state in five tested lesions and to
monosomy in one. Remarkably, with the exception of case
8P, all of the lesions carrying low c-Kit polysomy showed
CDKN2A loss. Lack of KIT protein was observed in 7/14
lesions, irrespective of gene status, and it was not associated
with the anomalies identified by mutational analysis or to
L842L polymorphism. However, the absence of KIT protein
seems to track with advanced disease, as four out of five
nodal or distant metastatic cases showed at least one null
lesion (5P, 7P, 9P, and 10P). Examples of variability in KIT
expression and in loss of CDKN2A (in all but one case, 3P)
are shown in Figure 1. In the familial series, one sample
showed an activating mutation in exon 18, S864F, which to
our knowledge is previously unreported, and one showed the
‘‘low-polysomy’’ condition (samples 2F and 5F; see Table 2
and Figure S1). All but two samples showed weak KIT-
positive staining.
BRAF and NRAS genes.We detected the BRAFV600E variant in
melanoma samples from 5/10 pediatric patients, whereas no
mutations were detected in BRAF exon 11 and in the NRAS
gene (Table 3). In the samples obtained from patients with
familial melanoma history, 4/9 tumor lesions harbored the
BRAFV600E mutation and no other alterations were found.
Five nevic lesions from three patients were analyzed and
found BRAF mutated in 1/3 patients (Table 3). On the whole,
BRAFV600E mutations are shown in both groups at an
expected rate.
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Figure 1. CDKN2A/p16 and c-Kit/KIT in pediatric melanoma. (a–e) (3P): (a) primary melanoma showing strong KIT decoration of the junctional component
and weak immunostaining in melanoma, arrow, and (c) corresponding higher power magnification. Notice in primary melanoma, right aspect, the progressive
loss of staining throughout the tumor, from the more superficial component to the deeper one (arrowhead). (b and d) FISH analysis shows normal disomic
pattern for c-Kit and CDKN2A that, consistently, presents (e) nuclear and cytoplasmic immunostaining of p16. (f–j and k–o) (10P): two different synchronous
left lateral nodal metastases were analyzed in this patient: LN1 and LN2. LN1 (f–j): (f) H/E; (g) c-Kit low polysomy, and (h) KIT expression, coupled with
(i) CDKN2A HD and (j) null p16 immunophenotype. LN2 (k–o): (k) H/E, (l) c-Kit monosomy, and (m) null KIT immunostaining, coupled with (n) CDKN2A HeD
and (o) null p16 immunophenotype. (p–t) (7P): metastasis to the ovary. (p) H/E, (q) c-Kit disomic pattern, and (r) weak KIT expression coupled with (s) monosomy
of CDKN2A and (t) loss of p16. Scale bar: (a) 120mm, (c) and (m) 60 mm, others 30mm.
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Germ-line analysis of high- and low-penetrance melanoma
susceptibility genes CDKN2A, CDK4, and MC1R in pediatric
melanoma patients
Only 1/21 patients tested was shown to carry a CDKN2A
missense mutation, G101W/R115L, the most common
pathogenic mutation found in melanoma families in Medi-
terranean Europe countries including Italy (Mantelli et al.,
2002; Goldstein et al., 2006). This patient (19P) has a family
history of melanoma. Three patients carried other germ-line
sequence alterations: the silent mutation A134A in exon 2,
the mutation IVS2-97T/C in intron 2, and the change at
356G/A in the promoter region (Table 4; Figure S1). None
of these variants has been previously reported and none of
them alters protein sequence. However, in the case of IVS2-
97T/C and 356G/A, the mutations may cause a functional
impairment. Polymorphisms at nt500 (rs11515) and nt540
(rs3088440) in the 30 UTR were frequent; they represent
noncoding variants with unknown functional significance,
though possibly associated with melanoma disease (Orlow
et al., 2007). In contrast, single nucleotide polymorphism
191A/G in the promoter region was shown not to be
associated with melanoma disease (Harland et al., 2000).
One patient (4P) who had anaplastic astrocytoma 2 years
before the diagnosis of melanoma was shown to carry an
allelic deletion of the entire CDKN2A locus in a parallel
study analyzing patients with melanoma and nervous systems
tumors (data not shown). Altogether, 2/21 pediatric patients
carried a pathogenic CDKN2A alteration known to be
involved in genetic susceptibility. None of the patients
carried mutations in the CDK4 gene. In the familial
melanoma cohort studied, the pathogenic mutation
G101W/R115L was prevalent and other variants were
identified (Figure S1; Table S2).
Molecular typing of MC1R gene polymorphisms showed
that 9 pediatric patients carried consensus alleles or synon-
ymous variants and 12 carried non-synonymous gene
variants. Of the twelve carrying MC1R variants, four patients
had an ‘‘r/r’’ genotype, five were ‘‘r/con’’, and three ‘‘R/con’’
(Table 4). To compare this frequency 22 familial melanoma
patients were analyzed: 19/22 carried genotypes with MC1R
variant alleles (2 ‘‘R/R’’, 3 ‘‘R/r’’, 3 ‘‘r/r’’, 4 ‘‘R/con’’, and 7 ‘‘r/
con’’, as shown in Table S2; Po0.05% vs pediatric patients
by w2-test).
DISCUSSION
Owing to the rarity of pediatric melanoma, very few genetic
data have been produced so far.
At the somatic level we show that most pediatric
melanoma lesions harbor alterations in the CDKN2A and c-
Kit genes, whereas the occurrence of BRAFV600E mutations is
similar to that of adult melanoma. The great majority of
samples presented deletions at the CDKN2A locus by
cytogenetic analysis and demonstrated protein loss by IHC.
Although the analyzed sample set is small, the rate of
CDKN2A gene loss shown here by FISH is definitely
higher than that recently reported for sporadic adult
primary and secondary melanoma lesions when analyzed
with the same probe (Sini et al., 2008). c-Kit deregulation in
pediatric melanoma lesions was shown to occur quite
frequently, although not exclusively, because alterations
were found also in familial melanoma, including the S864F
mutation in the kinase domain altering the KIT function
(Table S3). Interestingly, a low-polysomic c-Kit status
paralleled CDKN2A HD in all but one case. This result
suggests that the coordinated loss of INK4A and gain of c-Kit
are associated in the development of pediatric melanoma.
The more frequent loss of KIT protein expression in pediatric
Table 3. Mutational analysis of BRAF and NRAS genes
in melanoma lesions and in nevi
Patient Sample
BRAF1
exon 11-15
NRAS1
exon 1-2
1P P wt wt
2P P wt wt
3P P V600E
4P P1 wt wt
P2 wt wt
P3 wt wt
5P P1 V600E
LN wt wt
P2 wt wt
6P P wt wt
LN wt wt
7P OVM V600E
LN wt wt
8P SCM V600E
9P LN V600E
11P P wt wt
1F P V600E
P wt wt
2F nj wt wt
nc wt wt
P V600E
cdc V600E
3F P wt wt
4F nj wt wt
5F LN V600E
6F P wt wt
7F nd wt wt
8F P wt wt
9F CM V600E
10F P wt wt
cdc, congenital dysplastic compound; CM, cutaneous metastasis; LN,
nodal metastasis; nc, compound nevus; nd, dermal nevus; nj, junctional
nevus; OVM, ovarian metastasis; P, primary tumor; SCM, subcutaneous
metastasis.
1NRAS and BRAF exon 11 sequence analysis was performed exclusively
for BRAF exon 15 wild-type samples.
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tumors compared to familial primary tumors seems to
correlate with disease progression. In all but one case (6P)
where both primary and metastasis were available, KIT
expression was absent in the metastatic sample. This finding
parallels data showing that KIT expression progressively
decreases during local tumor growth and dermal invasion, as
observed in one case from our study (Figure 1). According to
the literature, KIT expression is generally lost in metastases
(Shen et al., 2003).
Regarding our identified BRAF mutations, the change
resulted in the BRAFV600E variant, which occurs in 30–70% of
adult sporadic melanoma samples (Daniotti et al., 2004;
Curtin et al., 2005). This alteration was detected in pediatric
lesions as well as in familial melanoma lesions and in nevi
from these patients, confirming previously reported data
(Pollock et al., 2003; Gast et al., 2005). This result also
indicates that the BRAFV600E mutation is shared by most
melanoma and precursor lesions in patients with a genetic
susceptibility.
We show here that at the germ-line level, few pediatric
melanoma patients show CDKN2A sequence alterations; in
contrast, a difference between pediatric and familial patients
is shown in the frequency of MC1R variants. Germ-line
mutations in CDKN2A are the strongest risk factors for
melanoma identified to date. In the Italian population, 7–40%
of melanoma cases with a family history were shown to carry
an alteration in CDKN2A gene (Fargnoli et al., 1998; Della
Torre et al., 2001; Mantelli et al., 2002; Landi et al., 2004;
Gensini et al., 2007), whereas its occurrence in sporadic
melanoma patients is 1–2% (Casula et al., 2007), as
confirmed in a recent international population-based study
(Berwick et al., 2006). In previous studies, in the Australian
and Swedish populations, CDKN2A mutations have not been
detected in childhood melanoma without a family history
(Whiteman et al., 1997; Youl et al., 2002; Berg et al., 2004).
Our results show that few mutations are detected also by
extending the sequence analysis of the CDKN2A locus to
include exon 1b, the promoter, the 30 and 50 UTR and part of
Table 4. Germ-line analysis of melanoma susceptibility genes in pediatric melanoma patients
p16/ARF1 CDK41 MC1R
1
Patient Prom 50 UTR exon 1a-1b-2–3 30 UTR Exons 2-5-8 Variants Genotype2
1P wt wt wt R151C (H217H, G234G) R/con
2P (A134A) wt wt V60L3 (T314T3) r/r
3P wt wt nt540 C/T wt V60L r/con
4P4 wt wt wt wt wt wt
5P wt wt wt wt wt wt
6P wt wt nt540 C/T wt R151C R/con
7P 356 G/A wt wt wt V60L r/con
8P wt wt nt500 C/G wt wt wt
9P IVS2-97T/C wt wt V60L3 (Y182Y, T314T3) r/r
10P wt nt500 C/G wt (T314T3) wt
11P 191 G/G1 wt nt500 C/G wt V60L r/con
12P 191 A/G wt wt wt V60L3 (T314T) r/r
13P wt wt wt wt V60L, V92M (T314T) r/r
14P wt wt wt wt wt wt
15P wt wt wt wt (L263L) wt
16P 191 G/G3 wt nt500 C/G; nt540 C/T wt V92M (T314T) r/con
17P 191 G/G3 wt nt540 C/T wt V60L (T314T) r/con
18P wt wt nt500 G/G3 wt wt wt
19P wt G101W wt wt5 wt wt
20P 735 G/A; 191 A/G wt nt500 C/G wt5 R151C R/con
21P wt wt wt wt5 wt wt
con, consensus of MC1R sequence; wt, wild type.
1Mutations are shown in bold; synonymous polymorphisms or silent alterations are indicated into brackets; blanks represent samples that were unavailable
or that were unable to be evaluated.
2MC1R variants are classified as R and r as previously reported (Kanetsky et al, 2006).
3Homozygous polymorphism.
4Patient 4P is a carrier of an allelic deletion of the CDKN2A locus.
5CDK4 mutation analysis of exon 2.
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introns 1 and 2. In fact, we found out that besides one patient
carrying the G101W mutation in CDKN2A exon 2, two
patients carried mutations in the promoter and intron 2
regions. Noncoding region variants are considered of an
uncertain significance, because their effect at the protein
level is difficult to be demonstrated. These regions may
theoretically regulate gene expression by controlling nuclear
export, polyadenylation, translation rates, and mRNA degra-
dation. As an example, nt540 and nt500 in the 30 UTR, which
may have such a regulatory effect on mRNA, have been
associated with melanoma in some studies (Aitken et al.,
1999; Kumar et al., 2001; Orlow et al., 2007). These variants
are common in the patients analyzed here. Our analysis,
however, does not exclude the possibility that allelic
deletions of the CDKN2A gene exist, which are not
detectable through the direct gene sequencing because of
the presence of the wild-type allele. Indeed, one of the
pediatric patients studied here was carrier of a de novo allelic
deletion of the entire CDKN2A locus (Della Torre G,
unpublished data).
Our results indicate thatMC1R variant genotypes are not a
necessary condition for melanoma to develop in pediatric
age. MC1R is the key gene regulating pigmentation in
humans; it is highly polymorphic and more than 77 human
alleles with non-synonymous changes have been identified
(Kanetsky et al., 2006). These variants can result in partial—
variants ‘‘r’’—or complete—variants ‘‘R’’—loss of the recep-
tor’s signaling ability (Sturm et al., 2003).MC1R is considered
a low-penetrance melanoma gene (Box et al., 2001), and it
modifies melanoma risk in families segregating CDKN2A
mutations (Landi et al., 2005; Fargnoli et al., 2006a).
Although the small number of cases analyzed here may have
an effect on statistical significance, in pediatric patients
MC1R variants are detected at a lower frequency than in
familial patients (Table 4; Table S2). In comparison with
published studies with Italian individuals, the frequency of
MC1R variants in pediatric patients is lower than that
reported for sporadic melanoma population in large studies
(Kanetsky et al., 2006) and analogous to those reported for
the Italian healthy population (Fargnoli et al., 2006b;
Gerstenblith et al., 2007).
In conclusion, our results show that pediatric melanoma
lesions carry a higher number of acquired somatic alterations
than familial adult cases (Figure 2). Because of the small
number of children included in this series it is not possible to
see whether different genetic alteration patterns characterize
lesions in prepubertal and postpubertal patients. Pediatric
melanoma patients rarely carry germ-line CDKN2A patho-
genic mutations and do not necessarily harbor germ-line
MC1R variants. Although the importance of MC1R gene
variants in childhood melanoma cannot be completely ruled
out, it can be speculated that the total UV exposure in
children is much shorter than that of adult patients, and that
other genes associated with melanoma susceptibility in
children might include other pigmentation-related genes
recently identified (Sulem et al., 2007). The high occurrence
of associated CDKN2A/p16 and c-Kit/KIT changes suggests a
high level of genomic instability. In fact, a heterogeneous
pattern of alterations was shown not only in different
metastatic deposits but also in the same group of locoregional
synchronous nodal metastases from the same patient
(Figure 1). Further support to this evidence is given by the
recently reported occurrence of microsatellite instability and
loss of heterozygosity in pediatric melanoma that could
associate with mutations related to early onset (Uribe et al.,
2005), suggesting the existence of distinct molecular tumori-
genic pathways underlying the development of melanoma in
children and adults, as hypothesized for other pediatric
tumors (Nakamura et al., 2007). However, further investiga-
tion is required to delineate the pathophysiology of childhood
melanoma and evaluate possible defects in DNA repair
systems. Furthermore, although c-Kit gene amplifications or
mutations have thus far been detected only in distinct
melanoma subtypes (Pache et al., 2003; Curtin et al., 2006;
Antonescu et al., 2007), our results show that c-Kit dereg-
ulation occurs quite frequently, at least in susceptible
patients.
The diagnoses of melanocytic lesions in children
often present diagnostic dilemmas, because Spitz nevi
can be very difficult to distinguish from melanomas. In
addition, because pediatric melanoma is such a rare
disease, the creation of a collection of the cases
occurring at the national level in the different European
countries aimed at widening the knowledge of the
genetic profile and improving the diagnoses and the quality
of cure of this rare childhood tumor would be advisable. In
this context, the present series is used by the Italian
cooperative group on Pediatric Rare Tumors (TREP) as
background for defining diagnostic and therapeutic recom-
mendations and to set up a cooperation network with
specialists (Ferrari et al., 2007).
MATERIALS AND METHODS
Samples
Two cohorts of 21 consecutive pediatric and 23 familial melanoma
patients were studied. Familial patients were selected because of two
melanoma cases in first-degree relatives, according to the guidelines
1F 5F 6F 8F 9F 10F2F
p16 protein loss by IHC 
p16 gain/loss by FISH
KIT gain/loss by FISH
KIT sequence alteratin
KIT protein loss by FISH
BRAF V600E mutation
1P 3P 5P 7P6P 8P 9P 10P
Figure 2. Occurrence of altered patterns for CDKN2A/p16, c-Kit/KIT, and
BRAF at the somatic level in pediatric (left) and familial (right) melanoma
cases.
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of the Italian Society of Human Genetics in line with the
international guidelines (Kefford et al., 2002). Paraffin-embedded
tumoral samples were available for 11 pediatric and 10 adult
melanoma patients. In addition, five nevus samples from three adult
patients were also available. For six pediatric and seven adult
patients both the tumor sample and peripheral blood (PB) were
available, whereas for ten pediatric patients only PB was available
because tumors were excised elsewhere. Cases were classified
according to the revised American Joint Committee on Cancer
staging system (Balch et al., 2001). The study was approved by the
institutional review board, patients or their parents signed a written
informed consent to genetic investigation for research purpose, and
all procedures were approved by the local ethical guidelines. The
study adhered to the Declaration of Helsinki Principles.
Mutational analysis of CDKN2A, CDK4, MC1R, c-Kit, BRAF,
and NRAS genes
Genomic DNA was isolated from manually microdissected specimens
using the QIAamp DNA Mini Kit and from PB using the DNA Blood
Mini Kit (Qiagen, Crawley, West Sussex, UK). DNA obtained from
tumor samples was analyzed for mutations in c-Kit exons 9-11-13-17-
18, BRAF exons 11-15 and NRAS exons 1-2 as described previously
(Davies et al., 2002; Eskandarpour et al., 2003; Curtin et al., 2006;
Miselli et al., 2007). To enrich the amplification product, 40
additional cycles were performed using 4–8ml of the first PCR
reaction. DNA obtained from PB or from the normal tissue obtained
by microdissection was used for the analysis of germ-line MC1R,
CDKN2A, and CDK4 genes.MC1R exon 1 was amplified as described
previously (Kanetsky et al., 2004; Landi et al., 2006). PCR for
CDKN2A was performed as described (Kamb et al., 1994a); CDK4
exons 2-5-8 were amplified as described (Zuo et al., 1996). The PCR
products were directly sequenced using the automated 3100 Genetic
Analyzer (Applied Biosystems, Foster City, CA), and sequences were
analyzed with Sequencing Analysis and Vector NTI Suite version 7
software (Informax, Bethesda, MD). Previously unreported mutations
were classified by the use of Bioinformatics tools.
Immunohistochemistry
The most representative tissue samples were selected on the basis of
hematoxylin and eosin staining and IHC analysis was carried out
on 2 mm sections by the peroxidase-streptavidin method (Dako,
Glostrup, Denmark). The anti-p16 mAb (NeoMarkers, Fremont, CA)
was used at 1:100 after antigen retrieval in citrate buffer at 95 1C (in
autoclave) for 15minutes, and the anti-KIT rabbit polyclonal
antibody (A4502; Dako) was used at a 1:50 dilution after antigen
retrieval as above for 6minutes. Stains were developed with 3,3-
diaminobenzidine (Sigma, St. Louis, MO).
Fluorescence in situ hybridization
FISH analysis was performed as previously described (Perrone et al.,
2006). For the 9p21 locus, the c5 cosmid and the BAC clone RP11-
149I2 were used. The c5 cosmid spans about 50 kb of the
chromosomal region from the CDKN2A to the CDKN2B gene,
whereas RP11-149I2 encompasses both loci but includes a telomeric
region downstream exon 3 and spans about 100 kb (Kamb et al.,
1994b; Randerson-Moor et al., 2001). For the c-Kit gene, the BAC
clone RP11-586A2 was used (Miselli et al., 2007). Probes RP11-
149I2 and RP11-586A2 were kindly provided by Professor M
Rocchi, University of Bari, Italy. On average, 40 nuclei were
analyzed and the hybridization patterns were defined depending on
the number of signals. For the CDKN2A gene, the wild-type disomic
pattern was indicated by the presence of two CEP9 signals associated
with two gene signals (ratio gene/CEP9B1); the HD was determined
by the presence of only two CEP9 signals (ratio gene/CEP9B0); the
hemizygous deletion was determined by the presence of two CEP9
signals and only one gene signal (ratio gene/CEP9 B0.5). For the c-
Kit gene, the hybridization patterns were defined according to the
criteria previously described (Miselli et al., 2007); a ‘‘low-polysomy’’
condition was defined by the presence of three or four signals for
both probes in o40% of nuclei.
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